Citi analyst Geoff Meacham has maintained their bullish stance on REGN stock, giving a Buy rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Geoff Meacham has given his Buy rating due to a combination of factors that highlight Regeneron’s strategic positioning and growth potential. The recent FDA approval for Eylea-HD, specifically targeting retinal vein occlusion and expanded dosing, is seen as a significant catalyst for the Eylea franchise. This approval is expected to enhance Eylea’s competitive stance against Roche’s Vabysmo in the anti-VEGF market, potentially driving a notable performance improvement by the first quarter of 2026.
Over the long term, Meacham anticipates the anti-VEGF market will segment into distinct niches, with Eylea-HD capturing a substantial market share of 20-25%. The projected sales for Eylea-HD are expected to reach $2.0 billion by 2026 and $3.2 billion by 2030, contributing to the overall Eylea franchise sales. Despite some challenges, such as the pending PFS approval, Regeneron’s proactive measures and strategic collaborations are expected to mitigate these issues, supporting the Buy rating with a target price of $700.
According to TipRanks, Meacham is a 4-star analyst with an average return of 6.9% and a 56.49% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and Vertex Pharmaceuticals.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $836.00 price target.